Episodes

  • Dorian Haci talks Neurotech Chips and BCI
    Nov 16 2026

    What will it take to make neurotechnology part of everyday life? In this episode, Adam Fraser is joined by Dorian Haci, co-founder and CEO of MintNeuro, to explore the business behind the chips that power neural devices and BCIs. In their conversation, Dorian shares his perspective on building a company that helps other innovators move forward and turns scientific ambition into something people can use. They explore his ambition to make neurotech more accessible, the importance of creating real-world value and the possibilities of a closer relationship with technology. They also delve into the drive to solve meaningful problems, the value of learning from others and the long-term view behind lasting innovation. Tune in to learn about the decisions and relationships shaping neurotech’s next chapter.

    Key Points From This Episode:

    • [01:33] Meet Dorian and hear how his electronics background led him to MintNeuro.
    • [02:56] Discover why Dorian chose to use electronics to address neurological conditions.
    • [03:58] Learn why hardware bottlenecks caused MintNeuro’s move out of academia.
    • [06:17] Understand how neurotech chips differ from processors used for computing.
    • [09:22] Explore why MintNeuro builds modular, function-specific chips for neural devices.
    • [12:25] Hear why Dorian favours close customer partnerships over selling off-the-shelf chips.
    • [16:16] Unpack how he defines the BCI landscape and its place within wider neurotech.
    • [22:05] Where companies could compete as the BCI supply chain becomes specialised.
    • [27:31] Uncover why investors are backing BCI despite its long path to commercial scale.
    • [31:13] Assess how grants and investors have supported MintNeuro’s progress to market.
    • [33:41] MintNeuro's funding requirements and their strategy for scaling globally.
    • [36:33] Find out how Dorian adapted from designing chips to leading a business.
    • [39:33] Final takeaways and how to connect with Dorian and follow MintNeuro’s progress.

    Links Mentioned in Today’s Episode:

    Dorian Haci on LinkedIn

    MintNeuro

    MintNeuro on LinkedIn

    Motif

    Amber Therapeutics

    Episode 5: Naveen Rao Talks Neurotech Market Dynamics

    Phase Lock

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast

    Show More Show Less
    40 mins
  • Daniel Månsson Talks tDCS, Depression and Scaling a Start Up
    Nov 2 2026

    Flow Neuroscience has developed an at-home brain stimulation treatment for depression, but bringing it to market has involved years of clinical research, regulatory approvals, and commercial challenges. In this episode of the Business of Neurotech Podcast, host Adam Fraser welcomes Daniel Månsson, Co-founder and CEO of Flow Neuroscience, to explore the story behind the technology and the company's expansion into the U.S. market. Daniel explains how his background in clinical psychology led him to start the company, how transcranial direct current stimulation (tDCS) works, and the benefits and challenges of the company’s early direct-to-consumer model in Europe. He shares how clinical trials helped secure FDA approval and how Flow is approaching its recent U.S. launch. The discussion also covers the company's funding journey, the challenges of moving from research to commercial growth, and its long-term ambitions. Listen in to hear Daniel's vision for making depression treatment more accessible and discover how precision psychiatry could help match patients with the treatments most likely to work for them.

    Key Points From This Episode:

    • [01:11] How Daniel’s diverse career background led him to co-found Flow Neuroscience.
    • [02:09] Daniel's perspective on the challenges of diagnosing and treating depression.
    • [05:32] What inspired Daniel to found Flow Neuroscience with his partner.
    • [08:31] How tDCS works, compares with other treatments, and is used in Flow's headset.
    • [13:41] Flow's early direct-to-consumer model in Europe and its benefits and challenges.
    • [15:53] Why Flow was perceived as a wellness product despite its clinical evidence.
    • [17:54] Understand what it took to bring Flow's technology into the U.S. market.
    • [19:29] How Flow's U.S. prescription model differs from its European approach.
    • [21:37] Unpack the clinical trial results that helped Flow secure FDA approval.
    • [25:28] Hear about Flow's ongoing research into other potential treatment applications.
    • [27:17] Explore Flow's funding journey and the challenges of scaling a science-led business.
    • [32:10] Daniel's long-term vision for Flow and the potential of precision psychiatry.
    • [34:00] Find out how to connect with Daniel and learn more about Flow Neuroscience.

    Links Mentioned in Today’s Episode:

    Daniel Månsson on LinkedIn

    Flow Neuroscience

    Flow Neuroscience | Research and Clinical Trials

    Empower Clinical Trial — Nature Medicine

    Khosla Ventures

    Episode 4: Mariam Khayretdinova talks EEG, AI and Psychiatry

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    35 mins
  • Chay Carter Talks Neurotech Recruitment and Market Trends
    Oct 19 2026

    What can the people building neurotech teams tell us about where the industry is heading? In this episode of The Business of Neurotech, Adam Fraser speaks with Chay Carter, founder of Carter Sciences and co-founder of reccy neuro, to offer a recruitment-focused view of the sector. Chay brings decades of experience in recruitment and psychology, combining specialist hiring with research, newsletters and insights from the people developing the technology. In their conversation, Chay shares how he came to focus on neurotech and what he has learnt about helping companies build the teams they need. They also discuss the influence of AI on recruitment, the broader trends he is seeing across neurotech and how his research and media work connect with the changing needs of the industry. Tune in for Chay’s perspective on people, relationships and how the market is shaping neurotech’s next chapter.

    Key Points From This Episode:

    • [01:24] Trace how Chay’s career led to specialist neurotech recruitment and reccy neuro.
    • [07:37] Discover what makes a strong founding team beyond scientific and technical talent.
    • [09:39] Learn how hiring priorities change as startups move towards commercialisation.
    • [12:03] Understand why big-company experience can be a shock to the system at a startup.
    • [13:59] Explore how market trends shape his recruitment and fractional support for startups.
    • [18:39] Examine where AI, BCI, and implantable devices are changing the demand for talent.
    • [21:07] Hear why AI applications and screening still require real human conversations.
    • [23:46] Consider whether AI can replace the hands-on work neurotech companies need.
    • [25:24] Follow how Chay transforms global news into newsletters, interviews, and deep dives.
    • [29:26] Unpack the scale and pace of neurotech’s growth and difficulties defining the sector.
    • [31:50] Assess how his media and market data could become a business in their own right.
    • [34:53] Compare US dominance with the neurotech activity happening around the world.
    • [38:04] Find out why wearable brain-reading devices still face a form factor challenge.
    • [39:05] Connect with Chay and access his research and free neurotech company database.

    Links Mentioned in Today’s Episode:

    Chay Carter on LinkedIn

    Carter Sciences

    reccy neuro

    Carter Sciences | The Neurotech Newsletter

    The Open Loop Podcast

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    40 mins
  • Paul Le Floch talks BCI, Coma and Start Up Dynamics
    Oct 5 2026

    How can softer materials make implantable brain-computer interfaces safer, more stable and clinically useful? In this episode of The Business of Neurotech, Adam Fraser is joined by Dr Paul Le Floch, co-founder and CEO of Axoft, to explore how his materials science background led to Fleuron, a soft neural interface platform designed to reach deep brain regions while maintaining high-density recordings. Dr Le Floch explains why Axoft is initially focusing on disorders of consciousness, how the company is taking a stepwise path through FDA clearance and what its early clinical work revealed about turning novel biomaterials into medical devices. He also discusses the realities of raising a $55 million Series A, competing in a fast-moving BCI market, financing research through materials sales and learning to pitch a long-term vision as a scientist-founder. Tune in to learn what it takes to build an invasive BCI company focused on better materials, unmet clinical needs and patient impact.

    Key Points From This Episode:

    • [01:29] Dr Le Floch’s path from materials science at Harvard to founding Axoft.
    • [03:21] Discover why the brain’s electrical complexity drew him into neuroscience.
    • [04:57] Unpack how Fleuron’s softness aims to improve compatibility with brain tissue.
    • [06:44] Explore why stable neural data links efficacy with reduced tissue disruption.
    • [08:58] Compare invasiveness with signal quality and where Axoft sits on that continuum.
    • [12:19] Find out why disorders of consciousness became Axoft’s first clinical focus.
    • [16:26] Follow the roadmap from diagnosis and prognosis towards decoding communication.
    • [18:12] Understand Axoft’s stepwise regulatory strategy for a temporary inpatient device.
    • [20:15] He shares his experience working with the FDA in an emerging BCI category.
    • [21:34] Uncover the clinical evidence and commercial plan behind Axoft’s Series A.
    • [23:25] The clearance, manufacturing and clinical milestones needed for Series B funding.
    • [25:14] Gain insight into why BCI’s difficult venture capital environment is still worth the risk.
    • [28:47] Unpack Axoft’s strategy in a field of well-funded but complementary competitors.
    • [30:12] Hear how materials sales fund research while providing partnership opportunities.
    • [33:35] Why targeted stimulation that bridges devices and drugs is capturing his attention.
    • [35:11] Learn how scientist-founders can move from research to vision-led application.
    • [37:18] Final takeaways and how to learn more about Axoft and Dr Le Floch’s work.

    Links Mentioned in Today’s Episode:

    Dr Paul Le Floch on LinkedIn

    Axoft

    Axoft on LinkedIn

    Episode 5: Naveen Rao Talks Neurotech Market Dynamics

    Episode 8: Nicolas Vachicouras Talks BCI Market Dynamics and Start Up Life

    Episode 12: Matt Angle Talks Paradromics and BCI Market Dynamics

    Mass General Brigham

    FDA Breakthrough Devices Program

    iBCI Collaborative Community (iBCI-CC)

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    38 mins
  • Jordan DeKraker Talks Seed Funding, Brain AI and Epilepsy
    Sep 21 2026

    How can academic brain-imaging research become a practical clinical tool for people with drug-resistant epilepsy? In this episode of The Business of Neurotech, Adam Fraser is joined by Jordan DeKraker, co-founder and CEO of BrainScores and a postdoctoral researcher at the Montreal Neurological Institute, to discuss how he went from hippocampal mapping to building an AI-enabled neuroimaging company. In their conversation, Jordan talks about how his personal experience with epilepsy sharpened the company’s focus, what it takes to package open-source science into trustworthy software and why clinicians still need to stay in the loop. They also discuss early-stage funding, regulatory and market-entry decisions, interoperability, explainable AI and the wider role of precision imaging across neurotech. Tune in for a look at the business decisions behind bringing brain AI from the lab into clinical care with Jordan DeKraker.


    Key Points From This Episode:

    • [01:21] Jordan’s path from hippocampal research to founding BrainScores.
    • [05:08] Find out what HippUnfold revealed and why its potential matters.
    • [07:25] Hear how Jordan’s epilepsy experience shaped the company’s first focus.
    • [12:05] Meet the co-founders and see how their skills support the company’s vision.
    • [13:43] Examine BrainScores’ non-dilutive funding and ambitions for venture capital.
    • [15:19] Understand the software as a medical device model and its go-to-market plan.
    • [17:46] Learn how BrainScores is testing the market and the role of feedback from clinicians.
    • [19:53] Uncover what the company hopes to achieve with its open-source platform.
    • [23:17] Understand why clinicians must remain accountable within an AI-assisted workflow.
    • [25:33] Whether healthcare AI should augment expertise rather than replace it.
    • [27:24] The model interoperability needed to integrate various data sources and tools.
    • [31:21] Compare funding, capital and opportunities between Canada and the US.
    • [34:45] Explore BrainScores’ roadmap beyond epilepsy into age-related cognitive decline.
    • [36:29] He shares his view on the future of BCI and transcranial stimulation.
    • [38:10] Where to follow Jordan’s research and the latest work from BrainScores.


    Links Mentioned in Today’s Episode:

    Jordan DeKraker on LinkedIn

    The Neuro (Montreal Neurological Institute-Hospital)

    BrainScores

    BrainScores on LinkedIn

    McGill University

    HippUnfold

    The Human Connectome Project (HCP)

    Healthy Brains for Healthy Lives

    Centre for Aging + Brain Health Innovation

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast

    Show More Show Less
    39 mins
  • Matt Angle Talks Paradromics and BCI Market Dynamics
    Sep 7 2026

    For people who have lost the ability to speak, brain-computer interfaces (BCIs) could open a new path back to communication. In this episode, Adam Fraser speaks with Matt Angle, founder and CEO of Paradromics, about the company’s 11-year journey to build a BCI that can restore communication for people who have lost it. Matt explains why moving more neural data is central to BCI performance and how Paradromics is approaching safety, durability and clinical translation. He breaks down why speech restoration is the company’s first clinical focus, then unpacks what could come next, including movement applications, mood biomarkers and AI-enabled communication. The conversation also explores the company’s move from Silicon Valley to Austin, Texas, as well as the regulatory, reimbursement, funding and commercial realities of building in deep tech, and what it takes to turn frontier neuroscience into a durable company. Listen in for a closer look at Paradromics’ journey and the technology, capital and strategic thinking shaping the future of BCI.


    Key Points From This Episode:

    • [01:31] Discover how Matt’s neuroscience background led him to found Paradromics.
    • [03:18] Learn how BCI has shifted from pure science to an engineering challenge.
    • [04:53] Hear why Matt has stayed in the CEO role 11 years into the journey.
    • [07:34] Understand Paradromics’ focus on safety, durability and neural data.
    • [08:29] Why moving more neural data is central to building better BCI systems.
    • [14:00] Learn why speech restoration is Paradromics’ first clinical focus.
    • [15:20] Explore the broader medical applications Paradromics may pursue next.
    • [20:11] Find out why Paradromics moved from Silicon Valley to Austin, Texas.
    • [22:25] Matt’s perspective on FDA engagement, regulation and reimbursement pathways.
    • [27:26] Explore how Paradromics thinks about funding, competition and investor alignment.
    • [33:28] Hear Matt’s view on IPO potential and the wider BCI ecosystem.
    • [35:18] Why “invasive” is not always the best way to assess BCI risk.
    • [39:29] Matt’s advice for founders building deep tech companies.


    Links Mentioned in Today’s Episode:

    Derrick Matthew Buchanan on LinkedIn

    Canada Neuro

    Royal World Archive

    Derrick Buchanan, Ph.D. Clinical Neuroscience

    ‘The complex landscape of TMS devices: A brief overview’

    ‘A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices’

    ‘Should rTMS be considered a first-line treatment for major depressive episodes in adults?’

    ‘Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy’

    ‘Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression’

    Matt Angle on LinkedIn

    Paradromics

    Paradromics | Connexus

    Matt Angle on Substack

    ‘CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices’

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    43 mins
  • Derrick Buchanan talks Stanford, Transcranial Magnetic Stimulation and Neurotech
    Aug 24 2026

    Brain stimulation is moving from specialist clinics towards faster, more personalised and scalable care. In this episode, Adam Fraser speaks with Dr Derrick Buchanan, a clinical neuroscientist in Stanford’s Brain Stimulation Lab, entrepreneur, author and speaker whose work spans precision brain imaging, neuromodulation and mental health. Derrick discusses his path from Canada to Stanford and explores how the university turns research into companies. He unpacks how transcranial magnetic stimulation works, why adoption still lags behind its clinical promise, and where portable devices may take the field. They also explore the neurotech ecosystem and the long-term investment logic behind BCI. Tune in to hear how science, commercialisation and access could shape the next generation of brain care with Dr Derrick Buchanan.

    Key Points From This Episode:

    • [01:50] Discover how Dr Buchanan’s career path shaped his work and entrepreneurship.
    • [09:22] Explore what makes Stanford the ideal place for cutting-edge research.
    • [11:56] Unpack how Stanford handles IP, licensing and startup ownership.
    • [16:16] Learn how transcranial magnetic stimulation (TMS) stimulates the brain.
    • [23:30] Uncover the barriers holding back the wider adoption of TMS.
    • [28:29] Find out how portable TMS could expand access and when to expect it.
    • [31:09] Hear his perspective on applying neurotech across imaging, stimulation and BCI.
    • [34:28] Dr Buchanan explains how invasive and non-invasive tools can coexist.
    • [38:31] Final takeaways and why investors are betting heavily on BCI.

    Links Mentioned in Today’s Episode:

    Derrick Buchanan

    Derrick Buchanan on X

    Stanford Medicine

    The Brain Stimulation Lab (BSL)

    Canadian Institutes of Health Research

    Stanford Office of Technology Licensing

    Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)

    Motif Neurotech

    Episode 6: David Eagleman Talks Media, Startups, and Neuroscience

    Episode 4: Mariam Khayretdinova talks EEG, AI and Psychiatry

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast


    Show More Show Less
    45 mins
  • Matias Serebrinsky talks frontier brain and mental health VC investing
    Aug 10 2026

    What makes an emerging technology bold enough and a founder exceptional enough to justify taking an early-stage risk? In this episode of The Business of Neurotech, Adam Fraser sits down with Matias Serebrinsky, Founding Partner at PsyMed Ventures, a specialist venture capital fund investing in frontier brain and mental health technologies. Matias brings a dual perspective as both a former startup founder and an early-stage investor who previously supported AI companies during a pivotal period in the industry’s growth. In this conversation, he reflects on how breakthrough technologies move from research labs into real-world products and what it takes for scientific drive to become a venture-scale company. They also discuss the evolution of neurotechnology as an investment category, the realities of backing high-risk frontier science, and how PsyMed assesses early-stage opportunities across brain-computer interfaces, neuromodulation, mental health innovation and more. Tune in for an investor’s view of the people and technologies driving frontier neuro forward.

    Key Points From This Episode:

    • [01:15] Explore Matias’ journey from startup founder and NVIDIA to neuro investing.
    • [05:37] Uncover the three qualities PsyMed looks for in an early-stage investment.
    • [06:54] Explore Matias’ broad definition of neurotech and the market behind it.
    • [08:30] He shares PsyMed’s approach to investing early and supporting founders.
    • [12:55] Whether specialist and generalist funds will grow as more investors join.
    • [15:35] Consider what major exits could mean for neurotech’s investment appeal.
    • [18:54] Learn which opportunities are currently capturing PsyMed’s attention.
    • [22:18] Hear about a BCI company taking a different path to developing neurotech.
    • [28:34] Discover the role capital plays in turning science into a successful company.
    • [30:58] Unpack the different hardware approaches to neuromodulation.
    • [34:15] Understand what changes when a wellness product enters medical territory.
    • [36:28] Matias’ advice for researchers considering the startup journey.

    Links Mentioned in Today’s Episode:

    Matias Serebrinsky on LinkedIn

    PsyMed Ventures

    PsyMed Ventures on Substack

    Business Trip Podcast

    ‘The State of Frontier Neuro’

    Motif

    Adam Fraser on LinkedIn

    Omniscient Neurotechnology

    The Business of Neurotech Podcast

    Show More Show Less
    39 mins